The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
05 05 2022
Historique:
received: 21 03 2022
revised: 24 04 2022
accepted: 04 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

HIV-positive patients may present lungs with multiple infections, which may hinder differential diagnoses and the choice of treatment in the course of COVID-19, especially in countries with limited access to high-standard healthcare. Here, we aim to investigate the association between radiological changes and poor COVID-19 outcomes among HIV-positive patients from Central and Eastern Europe. Between November 2020 and May 2021, the Euroguidelines in Central and Eastern Europe Network Group started collecting observational data on HIV and COVID-19 co-infections. In total, 16 countries from Central and Eastern European submitted data (eCRF) on 557 HIV-positive patients. The current analyses included patients who had a radiological examination performed. Logistic regression models were used to identify the factors associated with death, ICU admission, and partial recovery (poor COVID-19 outcomes). Factors that were significant in the univariate models (p < 0.1) were included in the multivariate model. Radiological data were available for 224 (40.2%) patients, 108 (48.2%) had computed tomography, and 116 (51.8%) had a chest X-ray. Of these, 211 (94.2%) were diagnosed using RT-PCR tests, 212 (94.6%) were symptomatic, 123 (55.6%) were hospitalized, 37 (16.6%) required oxygen therapy, and 28 (13.1%) either died, were admitted to ICU, or only partially recovered. From the radiologist’s description, 138 (61.6%) patients had typical radiological changes, 18 (8.0%) atypical changes, and 68 (30.4%) no changes. In the univariate models, CD4 count (OR = 0.86 [95% CI: 0.76−0.98]), having a comorbidity (2.33 [1.43−3.80]), HCV and/or HBV co-infection (3.17 [1.32−7.60]), being currently employed (0.31 [0.13−0.70]), being on antiretroviral therapy (0.22 [0.08−0.63]), and having typical (3.90 [1.12−13.65]) or atypical (10.8 [2.23−52.5]) radiological changes were all significantly associated with poor COVID-19 outcomes. In the multivariate model, being on antiretroviral therapy (OR = 0.20 [95% CI:0.05−0.80]) decreased the odds of poor COVID-19 outcomes, while having a comorbidity (2.12 [1.20−3.72]) or either typical (4.23 [1.05−17.0]) or atypical (6.39 [1.03−39.7]) radiological changes (vs. no changes) increased the odds of poor COVID-19 outcomes. Among HIV patients diagnosed with symptomatic SARS-CoV-2 infection, the presence of either typical or atypical radiological COVID-19 changes independently predicted poorer outcomes.

Identifiants

pubmed: 35632714
pii: v14050972
doi: 10.3390/v14050972
pmc: PMC9146246
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Références

PLoS One. 2020 Dec 17;15(12):e0243529
pubmed: 33332394
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
Radiol Case Rep. 2021 Oct 02;16(12):3685-3689
pubmed: 34630801
Infection. 2021 Dec;49(6):1079-1090
pubmed: 34059997
Front Med (Lausanne). 2020 Oct 21;7:555301
pubmed: 33195304
AIDS. 2020 Nov 1;34(13):F3-F8
pubmed: 32796217
Int J Infect Dis. 2020 Oct;99:119-121
pubmed: 32768700
AJR Am J Roentgenol. 2012 Jun;198(6):W555-61
pubmed: 22623570
World J Radiol. 2020 Aug 28;12(8):142-155
pubmed: 32913561
J Med Virol. 2021 Apr;93(4):2385-2395
pubmed: 33331656
Przegl Epidemiol. 2019;73(4):511-521
pubmed: 32237700

Auteurs

Justyna D Kowalska (JD)

Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.

Carlo Bieńkowski (C)

Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.

Lukáš Fleischhans (L)

Department of Infectious Diseases, 1st Faculty of Medicine, Faculty Hospital Bulovka Hospital, Charles University in Prague, 18081 Prague, Czech Republic.

Sergii Antoniak (S)

Viral Hepatitis and AIDS Department, Gromashevsky Institute of Epidemiology and Infectious Diseases, Amosova str. 5-a, 03038 Kyiv, Ukraine.

Agata Skrzat-Klapaczyńska (A)

Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.

Magdalena Suchacz (M)

Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, 01-201 Warsaw, Poland.

Nikolina Bogdanic (N)

School of Medicine, University Hospital for Infectious Diseases, University of Zagreb, Miorogojska 8, 10000 Zagreb, Croatia.

Deniz Gokengin (D)

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.

Cristiana Oprea (C)

Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, 030303 Bucharest, Romania.

Igor Karpov (I)

Department of Infectious Diseases, Belarusian State Medical University, Dzerginskogo 83, 220116 Minsk, Belarus.

Kerstin Kase (K)

West Tallinn Central Hospital, Paldiski Road 62, 10149 Tallin, Estonia.

Raimonda Matulionyte (R)

Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, 08410 Vilnius, Lithuania.

Antonios Papadopoulos (A)

Medical School, University General Hospital Attikon, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Nino Rukhadze (N)

Infectious Diseases, AIDS and Clinical Immunology Center, 16. Al Kazbegi Ave, 0102 Tblisi, Georgia.

Arjan Harxhi (A)

Infectious Disease Service, University Hospital Center of Tirana, Rr. Didres, Nr 372, 33979 Tirana, Albania.

David Jilich (D)

Department of Infectious Diseases, 1st Faculty of Medicine, Faculty Hospital Bulovka Hospital, Charles University in Prague, 18081 Prague, Czech Republic.

Botond Lakatos (B)

National Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, National Center of HIV, 1097 Budapest, Hungary.

Dalibor Sedlacek (D)

Faculty of Medicine in Plzeň, University Hospital Plzeň, Charles University, 30599 Plzen, Czech Republic.

Gordana Dragovic (G)

Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine; University of Belgrade, Dr Subotica 1/III, 24101 Belgrade, Serbia.

Marta Vasylyev (M)

Astar Medical Center, 79041 Lviv, Ukraine.

Antonia Verhaz (A)

Department for Infectious Diseases, Faculty of Medicine, University of Banja Luka, Republika Srpska, 78000 Banja Luka, Bosnia and Herzegovina.

Nina Yancheva (N)

Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Medical University of Sofia, 1233 Sofia, Bulgaria.

Josip Begovac (J)

School of Medicine, University Hospital for Infectious Diseases, University of Zagreb, Miorogojska 8, 10000 Zagreb, Croatia.

Andrzej Horban (A)

Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH